Literature DB >> 11991972

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

V Novitsky1, U R Smith, P Gilbert, M F McLane, P Chigwedere, C Williamson, T Ndung'u, I Klein, S Y Chang, T Peter, I Thior, B T Foley, S Gaolekwe, N Rybak, S Gaseitsiwe, F Vannberg, R Marlink, T H Lee, M Essex.   

Abstract

An evolving dominance of human immunodeficiency virus type 1 subtype C (HIV-1C) in the AIDS epidemic has been associated with a high prevalence of HIV-1C infection in the southern African countries and with an expanding epidemic in India and China. Understanding the molecular phylogeny and genetic diversity of HIV-1C viruses may be important for the design and evaluation of an HIV vaccine for ultimate use in the developing world. In this study we analyzed the phylogenetic relationships (i) between 73 non-recombinant HIV-1C near-full-length genome sequences, including 51 isolates from Botswana; (ii) between HIV-1C consensus sequences that represent different geographic subsets; and (iii) between specific isolates and consensus sequences. Based on the phylogenetic analyses of 73 near-full-length genomes, 16 "lineages" (a term that is used hereafter for discussion purposes and does not imply taxonomic standing) were identified within HIV-1C. The lineages were supported by high bootstrap values in maximum-parsimony and neighbor-joining analyses and were confirmed by the maximum-likelihood method. The nucleotide diversity between the 73 HIV-1C isolates (mean value of 8.93%; range, 2.9 to 11.7%) was significantly higher than the diversity of the samples to the consensus sequence (mean value of 4.86%; range, 3.3 to 7.2%, P < 0.0001). The translated amino acid distances to the consensus sequence were significantly lower than distances between samples within all HIV-1C proteins. The consensus sequences of HIV-1C proteins accompanied by amino acid frequencies were presented (that of Gag is presented in this work; those of Pol, Vif, Vpr, Tat, Rev, Vpu, Env, and Nef are presented elsewhere [http://www.aids.harvard.edu/lab_research/concensus_sequence.htm]). Additionally, in the promoter region three NF-kappa B sites (GGGRNNYYCC) were identified within the consensus sequences of the entire set or any subset of HIV-1C isolates. This study suggests that the consensus sequence approach could overcome the high genetic diversity of HIV-1C and facilitate an AIDS vaccine design, particularly if the assumption that an HIV-1C antigen with a more extensive match to the circulating viruses is likely to be more efficacious is proven in efficacy trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991972      PMCID: PMC137027          DOI: 10.1128/jvi.76.11.5435-5451.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Characterization of full-length HIV type 1 subtype C sequences from South Africa.

Authors:  J van Harmelen; C Williamson; B Kim; L Morris; J Carr; S S Karim; F McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-01       Impact factor: 2.205

2.  Timing of the introduction into Ethiopia of subcluster C' of HIV type 1 subtype C.

Authors:  A Abebe; V V Lukashov; T F Rinke De Wit; B Fisseha; B Tegbaru; A Kliphuis; G Tesfaye; H Negassa; A L Fontanet; J Goudsmit; G Pollakis
Journal:  AIDS Res Hum Retroviruses       Date:  2001-05-01       Impact factor: 2.205

Review 3.  Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

Authors:  P Gilbert; S Self; M Rao; A Naficy; J Clemens
Journal:  J Clin Epidemiol       Date:  2001-01       Impact factor: 6.437

4.  AIDS epidemic update: December 1999.

Authors: 
Journal:  AIDS Anal Afr       Date:  2000 Feb-Mar

5.  Evolutionary trees from DNA sequences: a maximum likelihood approach.

Authors:  J Felsenstein
Journal:  J Mol Evol       Date:  1981       Impact factor: 2.395

6.  Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.

Authors:  V Novitsky; N Rybak; M F McLane; P Gilbert; P Chigwedere; I Klein; S Gaolekwe; S Y Chang; T Peter; I Thior; T Ndung'u; F Vannberg; B T Foley; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Authors:  P Mooij; W M Bogers; H Oostermeijer; W Koornstra; P J Ten Haaft; B E Verstrepen; G Van Der Auwera; J L Heeney
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences.

Authors:  R Shankarappa; R Chatterjee; G H Learn; D Neogi; M Ding; P Roy; A Ghosh; L Kingsley; L Harrison; J I Mullins; P Gupta
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

View more
  62 in total

1.  Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates.

Authors:  Gillian M Hunt; Maria A Papathanasopoulos; Glenda E Gray; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

2.  Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.

Authors:  M Gordon; T De Oliveira; K Bishop; H M Coovadia; L Madurai; S Engelbrecht; E Janse van Rensburg; A Mosam; A Smith; S Cassol
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine.

Authors:  Udaykumar Ranga; Raj Shankarappa; Nagadenahalli B Siddappa; Lakshmi Ramakrishna; Ramalingam Nagendran; Marthandan Mahalingam; Anita Mahadevan; Narayana Jayasuryan; Parthasarathy Satishchandra; Susarla K Shankar; Vinayaka R Prasad
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

Authors:  Florence Doualla-Bell; Ava Avalos; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Ndwapi Ndwapi; Vladimir A Novitsky; Bluma Brenner; Maureen Oliveira; Daniella Moisi; Howard Moffat; Ibou Thior; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

6.  A systematic bioinformatics approach for selection of epitope-based vaccine targets.

Authors:  Asif M Khan; Olivo Miotto; A T Heiny; Jerome Salmon; K N Srinivasan; Eduardo J M Nascimento; Ernesto T A Marques; Vladimir Brusic; Tin Wee Tan; J Thomas August
Journal:  Cell Immunol       Date:  2007-04-16       Impact factor: 4.868

7.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Estimating selection pressures on HIV-1 using phylogenetic likelihood models.

Authors:  S L Kosakovsky Pond; A F Y Poon; S Zárate; D M Smith; S J Little; S K Pillai; R J Ellis; J K Wong; A J Leigh Brown; D D Richman; S D W Frost
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

10.  Functional Incompatibility between the Generic NF-κB Motif and a Subtype-Specific Sp1III Element Drives the Formation of the HIV-1 Subtype C Viral Promoter.

Authors:  Anjali Verma; Pavithra Rajagopalan; Rishikesh Lotke; Rebu Varghese; Deepak Selvam; Tapas K Kundu; Udaykumar Ranga
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.